Taysha Gene Therapies: Summary

Taysha Gene Therapies

Biotechnology, Gene Therapy, Rare Diseases, Central Nervous System Disorders

Taysha Gene Therapies aims to transform the lives of patients with CNS diseases through innovative gene therapy solutions.

Taysha Gene Therapies focuses on developing innovative gene therapies aimed at treating severe and life-threatening monogenic diseases of the central nervous system. Their primary goal is to improve the lives of patients affected by these genetic disorders through targeted therapeutic programs.

Focus on gene therapy for monogenic diseases; Expert team with a proven track record in gene therapy; Specific program for Rett syndrome (TSHA-102); Commitment to patient and caregiver support

Taysha's therapies are most valuable for patients suffering from monogenic diseases, particularly those with Rett syndrome and other CNS disorders.

Expertise in developing and commercializing gene therapies; Strong focus on patient-first approaches; Commitment to addressing rare diseases with significant unmet needs

The company has a strong scientific foundation, a dedicated team of experts, and a clear focus on impactful gene therapy programs.

Taysha positions itself as a leader in gene therapy for rare CNS diseases, emphasizing its commitment to patient care and scientific excellence.

The primary target users include patients with monogenic diseases, their families, healthcare professionals, and investors interested in innovative biotech solutions.

Learn About Our Science

• Gene Therapy

• Monogenic Diseases

• CNS Disorders

• Rett Syndrome

Bringing New Treatments to Life

Compassionate, authoritative, innovative

Taysha stands out in the market by focusing specifically on monogenic diseases of the CNS and leveraging a team with experience in the first FDA-approved gene therapy.

The brand identity is rooted in being an ally to the rare disease community, reflecting values of partnership and support.

2020-01-01

• RA Session